Finance Watch: Latest Slate Of VC Mega-Deals Led By China-Based Biopharmas
Chime Biologics, AffaMed, Brii Closed $100m-Plus Rounds
Executive Summary
Private Company Edition: The astonishing pace of venture capital investment in drug development continues with another $1.5bn in financings of $100m or more, including $152m for Pyxis and $126m for Omega. New VC funds also continue to launch, including RiverVest’s fifth fund, totaling $275m.
You may also be interested in...
Apnimed Moves Closer To Phase III With Sleep Apnea Drug
Apnimed is going to conduct one more Phase II study in sleep apnea, mainly to assess subjective endpoint questionnaires, and then hopes to launch a Phase III program by autumn of 2022.
Finance Watch: 2021 Now Has More IPOs Than 2020, But With $3.2bn Less
Public Company Edition: It took 256 days for 2021 to surpass the 2020 record of 86 biopharma initial public offerings in the US in one year. Also, Procaps raised $115m ahead of its SPAC merger and aTyr and bluebird raised $75m each.
Asher Bio Raises $108m For Immune Cell-Specific Therapies
With a CD8-targeting IL-2 mutein as its lead program, the start-up is developing cis-targeted immunotherapies that selectively target two molecules on the same immune cell for improved efficacy and safety.